Optimized Immunoassays Detect HBV in Oral Fluid Samples
By LabMedica International staff writers Posted on 05 Sep 2019 |
Image: A collection of whole saliva by the Salivette (absorbent) method. (a) Saliva is collected by chewing a cotton wool swab. (b) The swab containing saliva is placed in the tube of Salivette. (c) Centrifugation of the assemblage. (d) Saliva is separated from the swab and is ready for analysis (Photo courtesy of Sarstedt).
It is estimated that there are 257 million chronic hepatitis B (HBV) carriers worldwide, which highlights the substantial health, social, and economic burden of HBV. Screening of infected, cured and vaccinated individuals is necessary to identify the presence of chronically infected reservoirs, immune and susceptible individuals.
Currently, HBV infection diagnosis is performed using serum and plasma samples collected via venipuncture, which can be invasive, expensive, and potentially painful and arduous for some individuals including the elderly, obese, patients receiving hemodialysis, and drug users. In regions where financial resources are scarce, it would be beneficial to use methods with low cost and biological risk, such as oral fluid samples.
Scientists at the Oswaldo Cruz Institute (Rio de Janeiro, Brazil) optimized a commercially available assay for detecting total anti-HBc marker in oral fluid samples and evaluated its utility under real life conditions in different settings for the purposes of prevalence and diagnostic studies. The team collected blood samples, which were centrifuged for serum. Oral fluid was obtained using a commercial Salivette device. All serum samples were submitted to commercial Enzyme immunoassays (EIAs) to detect total anti-HBc antibodies directed against HBV surface antigen (anti-HBs) and HBsAg. All oral fluid samples were also tested with the Diasorin EIA ETI-AB-COREK-PLUS, designed to detect total anti-HBc in serum.
Optimization found the best elution buffer was PBS/BSA 0.5% and the best oral fluid sample volume was 100 µL. The team used these optimized parameters, 1,085 of the samples collected from the 1,296 participants did not detect anti-Hbc; in 211 samples, anti-HBc was detected. The oral fluid sensitivity was 52.6% and specificity was 96%. Sensitivity was higher in patients presenting with an active HBV infection compared with anti-HBc isolate and past infection, 92.7%, 43.2%, and 36.9%, respectively. In addition, sensitivity was higher in participants without active hepatitis C virus infection and also in participants who used injection drugs (85.9%).
The authors concluded that it was possible to optimize a commercial enzyme-linked immunosorbent assay for detecting anti-HBc in oral fluid samples where the highest concordance was found in ambulatory settings and among individuals with active infection. The study was published on July 17, 2019, in the journal BMC Infectious Diseases.
Related Links:
Oswaldo Cruz Institute
Currently, HBV infection diagnosis is performed using serum and plasma samples collected via venipuncture, which can be invasive, expensive, and potentially painful and arduous for some individuals including the elderly, obese, patients receiving hemodialysis, and drug users. In regions where financial resources are scarce, it would be beneficial to use methods with low cost and biological risk, such as oral fluid samples.
Scientists at the Oswaldo Cruz Institute (Rio de Janeiro, Brazil) optimized a commercially available assay for detecting total anti-HBc marker in oral fluid samples and evaluated its utility under real life conditions in different settings for the purposes of prevalence and diagnostic studies. The team collected blood samples, which were centrifuged for serum. Oral fluid was obtained using a commercial Salivette device. All serum samples were submitted to commercial Enzyme immunoassays (EIAs) to detect total anti-HBc antibodies directed against HBV surface antigen (anti-HBs) and HBsAg. All oral fluid samples were also tested with the Diasorin EIA ETI-AB-COREK-PLUS, designed to detect total anti-HBc in serum.
Optimization found the best elution buffer was PBS/BSA 0.5% and the best oral fluid sample volume was 100 µL. The team used these optimized parameters, 1,085 of the samples collected from the 1,296 participants did not detect anti-Hbc; in 211 samples, anti-HBc was detected. The oral fluid sensitivity was 52.6% and specificity was 96%. Sensitivity was higher in patients presenting with an active HBV infection compared with anti-HBc isolate and past infection, 92.7%, 43.2%, and 36.9%, respectively. In addition, sensitivity was higher in participants without active hepatitis C virus infection and also in participants who used injection drugs (85.9%).
The authors concluded that it was possible to optimize a commercial enzyme-linked immunosorbent assay for detecting anti-HBc in oral fluid samples where the highest concordance was found in ambulatory settings and among individuals with active infection. The study was published on July 17, 2019, in the journal BMC Infectious Diseases.
Related Links:
Oswaldo Cruz Institute
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia